A Post Marketing Clinical Study Utilizing DermaStream and Saline in Venous Ulcers
This study has been completed.
Sponsor:
EnzySurge
Information provided by (Responsible Party):
EnzySurge
ClinicalTrials.gov Identifier:
NCT01129986
First received: May 10, 2010
Last updated: March 19, 2012
Last verified: June 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
An open-label, prospective, controlled, two-step approach, post-marketing clinical study, applying DermaStream with saline streaming, in conjunction with a sustained multi-compression wrap, on healthy individuals and on patients with a venous stasis ulcer of the lower extremity.
| Condition | Intervention |
|---|---|
|
Venous Stasis Ulcers |
Device: DermaStream |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Post Marketing Clinical Study Utilizing DermaStream and Saline for Safety and Efficacy in Venous Stasis Ulcers of the Lower Extremity |
Further study details as provided by EnzySurge:
Primary Outcome Measures:
- Effect of DermaStream application [ Time Frame: Up to 21 days ] [ Designated as safety issue: No ]Reduction of slough tissue.
- Adverse Events [ Time Frame: Up to 21 days ] [ Designated as safety issue: Yes ]Incidence of investigational product related adverse events
- Effect of DermaStream application [ Time Frame: Up to 21 days ] [ Designated as safety issue: No ]Increase of granulation tissue
- Effect of DermaStream application [ Time Frame: Up to 21 days ] [ Designated as safety issue: No ]Pain recording on 1-10 scale
Secondary Outcome Measures:
- Usability [ Time Frame: 1-5 days ] [ Designated as safety issue: No ]Device malfunction reports and device replacements as measures of usability
- Wound size [ Time Frame: Up to 21 days ] [ Designated as safety issue: No ]Decrease in wound size at 2 weeks following last treatment day
- Quality of Life [ Time Frame: Up to 21 days ] [ Designated as safety issue: No ]Improved "Quality of Life" at 2 weeks following last treatment day
| Enrollment: | 15 |
| Study Start Date: | June 2009 |
| Study Completion Date: | November 2011 |
| Primary Completion Date: | July 2010 (Final data collection date for primary outcome measure) |
Intervention Details:
-
Device: DermaStream
Five treatment days. On each day DermaStream application for up to 4 hours of saline streaming.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
Group A:
- Must be male or female ≥18 years of age.
- Must be a healthy individual with intact skin
Group B:
- Must be male or female ≥18 years of age
- Must have a venous stasis ulcer between the knee and the ankle (including the lateral and medial malleolus). The ulcer must have the typical appearance of venous leg ulceration and the diagnosis of venous origin.
- Ankle Brachial Pressure Index of >0.8 -<=1.2
- Must have a venous leg ulcer between 3 cm up to 5.6 cm maximum and an ulcer duration of 60 days or greater prior to enrollment in the study
Exclusion Criteria:
Group A and Group B:
- Is unable to manage the self-treatment at home
- Is pregnant or is a nursing mother
- Is a woman of child bearing potential who is not using an adequate form of contraception (or abstinent)
- Is < 18 years of age
- With gross morbid obesity (i.e., a Body Mass Index ≥ 50)
- Has a known allergy to any of the drugs and/or dressings that are part of this protocol
- Has previously participated in this study
Group B:
- Has an ulcer that is deemed by the Investigator to be caused primarily by a medical condition other than venous insufficiency (e.g., diabetes, malignant ulceration [Marjolin's ulcer], vasculitis, etc.)
- Has evidence of current clinical infection although colonization is not an exclusion criterion (see definition section)
- Suffers from diabetes mellitus with HbA1c ≥ 10%
- Suffers from clinically significant arterial disease
- Has evidence of the ulcer and/or infection extending to the underlying muscle, tendon, or bone
- Has used any investigational drug(s)/device(s) within 30 days preceding screening or the physician or subject anticipates use of any of these treatments during the 2 weeks following start of the treatment portion of the study
- Has used or is anticipated to use any of the prohibited concomitant medications and treatments, as specified in study protocol, section 9.1.
- Suffers from a condition, other than venous insufficiency or venous hypertension which, in the opinion of the Investigator, would compromise the safety of the subject and/or the quality of the data.
- Suffers from a condition, other than venous insufficiency or venous hypertension which, in the opinion of the Investigator, would seriously interfere negatively with the normal wound healing process.
- Has laboratory values at screening outside ± 20% of the institution's normal range for any parameter other than HbA1c
- If laboratory values are outside ± 20% but the investigator deems the subject acceptable for enrollment, the Principal Investigator may approve the inclusion of the subject as long as there is no evidence of any comorbid condition where comorbidity could influence the trialIs using any of the prohibited concomitant medications or treatments.
- Wound surrounding skin not intact or has signs of active dermatitis or infection
- Wound over-bleeds
- Wound is severely ischemic
- Wound is larger than device aperture diameter
Contacts and Locations
More Information
No publications provided
| Responsible Party: | EnzySurge |
| ClinicalTrials.gov Identifier: | NCT01129986 History of Changes |
| Other Study ID Numbers: | ENZ-DER-003-US |
| Study First Received: | May 10, 2010 |
| Last Updated: | March 19, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by EnzySurge:
|
venous ulcer Dermastream |
Additional relevant MeSH terms:
|
Postphlebitic Syndrome Postthrombotic Syndrome Varicose Ulcer Ulcer Phlebitis Peripheral Vascular Diseases Vascular Diseases Cardiovascular Diseases Venous Insufficiency |
Venous Thrombosis Thrombosis Embolism and Thrombosis Varicose Veins Leg Ulcer Skin Ulcer Skin Diseases Pathologic Processes |
ClinicalTrials.gov processed this record on May 23, 2013